Gastrointestinal Stromal Tumor (GIST) Clinical Trial
Official title:
Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST): Detection and Correlation With Disease Status Assessed by Conventional Technique. Prospective Observational Study
This observational study is proposed to evaluate if the trend in the levels of cf-DNA evaluated on a sample of peripheral blood may be related to different clinical behaviors of the disease monitored by radiological investigations conducted.
Demetri and colleagues presented, at the AACR and ASCO Annual Meeting 2013, an exploratory
analysis to assess GIST genotypes on patients in the GRID study. Mutations in the KIT gene
were detected in 58 percent of the blood samples compared with 66 percent of the tumor
tissue samples (31). However, when focusing their analysis on secondary KIT mutations, which
are the mutations that drive resistance to targeted therapies like imatinib and sunitinib,
the researchers found mutations in 47 percent of blood samples compared with only 12 percent
of tissue samples. In addition, nearly half of blood samples in which secondary KIT
mutations were found, harbored multiple secondary mutations. Therefore, cf-DNA may become an
efficient marker of mutational GIST status and disease itself.
On this basis, this trial aims to evaluate whether tumor DNA carrying mutations (for KIT,
PDGFRα, BRAF, RAS, SDH) can be detected and quantified in the plasma of patients with GISTs,
either with active disease or during follow-up, and whether detection can be correlated with
the disease status.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02574663 -
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01991379 -
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
|
Phase 1/Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
Completed |
NCT01294202 -
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
|
Phase 2 | |
Completed |
NCT00785785 -
A Study of Nilotinib Versus Imatinib in GIST Patients
|
Phase 3 | |
Recruiting |
NCT01034670 -
Advanced Gastrointestinal Endoscopic Imaging
|
N/A | |
Completed |
NCT00867113 -
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Active, not recruiting |
NCT01391611 -
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
|
Phase 2 | |
Terminated |
NCT02452424 -
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03594422 -
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05453292 -
Endoscopic Ultrasound Radiofrequency Ablation for GISTs
|
N/A | |
Completed |
NCT00780494 -
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
|
Phase 2 | |
Recruiting |
NCT04557969 -
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
|
||
Completed |
NCT03404076 -
Unifying Advanced Treatment With Advanced Imaging
|
||
Recruiting |
NCT04821895 -
Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
|
||
Completed |
NCT01316263 -
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
|
Phase 2 | |
Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
Recruiting |
NCT01048281 -
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
|